About Daré Bioscience
Daré Bioscience is a company based in San Diego (United States) founded in 2005. The company has 23 employees. Daré Bioscience has completed 2 acquisitions, including Cerulean Pharma and Microchips Biotech. Daré Bioscience offers products and services including XACIATO and Drug Delivery Platform. Daré Bioscience operates in a competitive market with competitors including Atossa Therapeutics, Olema Oncology, PIQUR, Aspivix and Minerva Biotechnologies, among others.
- Headquarter San Diego, United States
- Employees 23
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website darebioscience.com
- Social LinkedIn X
- Legal Name Dare Bioscience, Inc.
- Annual Revenue$1.03 M (USD)10429.36as on Dec 31, 2025
- Net Profit-$13.4 M (USD)-230.55as on Dec 31, 2025
- EBITDA-$11.4 M (USD)50.3as on Dec 31, 2025
- Latest Funding Round$3.6M (USD), Grant
Nov 2025
- InvestorsNIH
& 3 more
- Employee Count23
- Investments & AcquisitionsCerulean Pharma
& 1 more
Products & Services of Daré Bioscience
Daré Bioscience offers a comprehensive portfolio of products and services, including XACIATO and Drug Delivery Platform.
Treatment for vaginal infections using clindamycin phosphate.
Wireless system for user-controlled drug administration.
Funding Insights of Daré Bioscience
- Total Rounds 17
- Last Round Grant — $3.6M
- First Round $20.69M
(Jul 2017)
- Investors Count 4
Latest 10 of 17 funding rounds of Daré Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $3.6M | Grant | – | Gates Foundation | – |
| Dec 2024 | $1M | Grant | – | – | |
| Jan 2024 | $750,000 | Grant | – | – | |
| Aug 2023 | $384,972 | Grant | – | – | |
| Nov 2022 | $584,986 | Grant | – | – | |
| Apr 2022 | $249,336 | Grant | – | – | |
| Sep 2021 | $300,000 | Grant | – | – | |
| Sep 2021 | $277,996 | Grant | – | – | |
| Sep 2020 | $900,000 | Grant | – | – | |
| Aug 2020 | – | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Daré Bioscience
Daré Bioscience has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Child health and human development services are provided nationwide. | 1962 | nichd.nih.gov | Bethesda, United States |
Investor details for Daré Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Daré Bioscience
24 people are tracked at Daré Bioscience (11 in leadership, 7 in board & advisors, 6 in team); the tracked headcount is 23.
| Name | Role | Group |
|---|---|---|
Sabrina Martucci Johnson | President & CEO | Leadership |
David Friend | Chief Scientific Officer | Leadership |
Mark Walters | VP, Operations | Leadership |
Christine Mauck | Medical Director | Leadership |
Elizabeth Proos | VP, Product Development | Leadership |
Jessica Hatheway | VP, Clinical Operations | Leadership |
Nicolas Pacelli | VP, Alliance Management & Business Development | Leadership |
Mardee Haring-Layton | VP, Accounting & Finance | Leadership |
Annie Thurman | Medical Director | Leadership |
Jennifer Kiang | Vice President Of Corporate Affairs And Development | Leadership |
Robert Charboneau | VP, Manufacturing & Supply Chain | Leadership |
Susan L. Kelley | Board Member | Board & advisors |
William H. Rastetter | Chairman of The Board | Board & advisors |
Jessica Grossman | Board Member | Board & advisors |
Gregory W. Matz | Board Member | Board & advisors |
Robin Steele | Board Member | Board & advisors |
Sophia N. Ononye-Onyia | Board Member | Board & advisors |
Andrew Goldstein | Medical Advisor | Board & advisors |
Michael Fabiunke | Research Associate | Team |
Lynn Murphy | Office Manager/executive Assistant | Team |
4 more people are available in the full profile.
Complete people profiles for Daré Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Daré Bioscience
Daré Bioscience is a publicly listed company on the NASDAQ with ticker symbol DARE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Apr 2014
- Listed onNASDAQ: DARE
- Listed entityDare Bioscience, Inc.
- Exchange sectorHealth technology
- ISINUS23666P2002
- Share price$0.77 (+0.16% on the day) · 2026-10-09
- Market capitalisation$15.2M
- EPS (diluted, trailing year)$-0.79
- Volume (last session)70,037
Financials of Daré Bioscience
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.0M | -$13.4M | -$11.4M |
| 2024 | $9,780 | -$4.0M | -$22.9M |
| 2023 | $2.8M | -$30.2M | -$30.8M |
| 2022 | $10.0M | -$30.9M | -$31.2M |
| 2021 | – | -$38.7M | -$39.0M |
Detailed financial statements for Daré Bioscience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Daré Bioscience
Daré Bioscience has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cerulean Pharma and Microchips Biotech.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Microchip implants for wireless drug delivery are developed. | microchipsbiotech.com | Lexington, United States | 1999 | Nov 2019 | $101.5M | |
Nanoparticle-drug conjugates are developed to target tumors and reduce toxicity. | ceruleanrx.com | Cambridge, United States | 2006 | Mar 2017 | •••• |
Complete acquisition details for Daré Bioscience
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Daré Bioscience
6 dated milestones of Daré Bioscience across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Daré Bioscience is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Cerulean Pharma.
- Funding First funding round of $20.7M.
- Acquisition Acquires Microchips Biotech.
- Funding Latest funding round, Grant, of $3.6M.
Competitors of Daré Bioscience
Daré Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Atossa Therapeutics, Olema Oncology, PIQUR, Aspivix and Minerva Biotechnologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atossatherapeutics.com | 2009 | Seattle, United States | $13.52M | 10 | Drugs for breast cancer treatment and prevention are developed. | |
| olema.com | 2007 | San Francisco, United States | $139M | 74 | Drug therapeutics for breast cancer treatment are developed. | |
| piqur.com | 2011 | Basel, Switzerland | $54.12M | 1 | Anti-cancer drugs are developed via PI3K and mTOR inhibition targeting. | |
| aspivix.com | 2015 | Lausanne, Switzerland | $7.01M | – | A next-generation suction-based cervical device for gynecology is provided. | |
| minervabio.com | 1999 | Waltham, United States | $18.86M | – | Cell therapy and antibodies are developed to treat cancer. | |
| ambagontx.com | 2020 | San Francisco, United States | $108M | – | Small-molecule therapeutics for cancer treatment are developed. | |
| mab-works.com | 2003 | Beijing, China | $214.44M | – | Anticancer therapies are developed using a dual-function antibody platform. | |
| eikonoklastes.com | 2019 | Columbus, United States | $20.76M | 3 | Tissue factor targeting therapeutics for cancer treatment are developed. |
Detailed competitors of Daré Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Daré Bioscience
The website of Daré Bioscience (darebioscience.com) receives about 8.3K visits a month.
- Monthly visits8.3K
▲ 20.9% vs previous month
Websites whose visitors overlap most with Daré Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aethlonmedical.com | 100% | 2K | #8,259,694 | View details | |
| carihealth.com | 34% | – | – | View details | |
| zerigohealth.com | 32% | 5.4K | #3,508,305 | View details | |
| alfascientific.com | 32% | – | #8,547,751 | View details | |
| ctkbiotech.com | 32% | 15.8K | #1,803,743 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Daré Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Daré Bioscience
Complete news archive for Daré Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Daré Bioscience
10 companies that operate in the same segment as Daré Bioscience (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 124.07 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 47 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Daré Bioscience
Daré Bioscience was founded in 2005 and raised its 1st funding round 12 years after it was founded.
Daré Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Daré Bioscience has 23 employees.
Annual revenue of Daré Bioscience is $1.03M as on Dec 31, 2025.
Dare Bioscience was founded in 2005 in San Diego, United States, and operates in the biotechnology sector focused on womens reproductive health. Non-hormonal contraceptive options are developed, with the lead product Ovaprene designed as an intravaginal ring. This ring incorporates a permeable mesh barrier to sperm and releases spermiostatic agents, including ascorbic acid and ferrous gluconate, for localized pH buffering and sperm immobilization over several weeks.
Daré Bioscience's top competitors include Atossa Therapeutics, Minerva Biotechnologies and Olema Oncology.
Daré Bioscience offers XACIATO and Drug Delivery Platform.
Yes, Daré Bioscience is publicly traded on NASDAQ under the ticker symbol DARE.
Daré Bioscience has made 2 acquisitions, including Cerulean Pharma, and Microchips Biotech.
Daré Bioscience has 4 investors. Key investors include NIH, Gates Foundation, HHS, and NICHD.
Daré Bioscience operates through Daré Bioscience, Inc..